SNTI
Senti Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.23
+0.84%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -22.0%
- EBIT
- +12.5%
- EPS
- +82.4%
- Free cash flow
- +21.9%
- Operating cash flow
- +21.5%
Forward estimates
Based on analyst estimates
- Revenue
- -73.1%
- EBITDA
- +87.4%
- EPS
- +88.1%
Three-year CAGR
- Revenue
- -81.2%
- EBITDA
- -5.3%
- EBIT
- -4.4%
- Net income
- -16.4%
- EPS
- +76.2%
- Free cash flow
- -5.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026